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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.052Proliferative vitreoretinopathy (PVR) exempliﬁes a disease that is difﬁcult to predict, lacks effective
treatment options, and substantially reduces the quality of life of an individual. Surgery to correct
a rhegmatogenous retinal detachment fails primarily because of PVR. Likely mediators of PVR are growth
factors in vitreous, which stimulate cells within and behind the retina as an inevitable consequence of
a breached retina. Three classes of growth factors [vascular endothelial growth factor A (VEGF-A),
platelet-derived growth factors (PDGFs), and non-PDGFs (growth factors outside of the PDGF family)]
are relevant to PVR pathogenesis because they act on PDGF receptor a, which is required for experi-
mental PVR and is associated with this disease in humans. We discovered that ranibizumab (a clinically
approved agent that neutralizes VEGF-A) reduced the bioactivity of vitreous from patients and exper-
imental animals with PVR, and protected rabbits from developing disease. The apparent mechanism of
ranibizumab action involved derepressing PDGFs, which, at the concentrations present in PVR vitreous,
inhibited nonePDGF-mediated activation of PDGF receptor a. These preclinical ﬁndings suggest that
available approaches to neutralize VEGF-A are prophylactic for PVR, and that antieVEGF-based therapies
may be effective for managing more than angiogenesis- and edema-driven pathological conditions.
(Am J Pathol 2013, 182: 1659e1670; http://dx.doi.org/10.1016/j.ajpath.2013.01.052)Supported by Department of Defense grant WB1XWH-10-1-0392 and
NIH grant EY012509 (A.K.), a Canadian Institutes of Health Research
(CIHR) fellowship (S.P.), Mukai Fund and Massachusetts Eye and Ear
Inﬁrmary (Boston) gifts (S.M.), and CIHR grants IAO 77736 and MOP
97806 (J.M. and J.C.).Proliferative vitreoretinopathy (PVR) is an example of
a disease that remains difﬁcult to manage despite multidecade
efforts to improve treatment options.1e4 It is the primary
reason for failure to correct a rhegmatogenous retinal detach-
ment (RRD) and occurs in 5% to 10% of patients, although in
cases involving penetrating ocular trauma, the incidence of
disease approaches 50%.5e8 RRDs are detachment caused by
a tear or other breaks in the retina, and can result inmore severe
retinal detachment (RD) or recurrent RD after surgical repair.
The formation of membranes on the surface of the retina is
associated with PVR and widely believed to promote this
condition. Repeat surgery is the only treatment option;
however, visual acuity better than 5/200 is achieved in less
than half of the eyes.9 Vision loss is permanent and thereby
substantially reduces the quality of life for these patients.
By using 2010 census data, an estimated 55,000 indi-
viduals in the United States experience an RRD annually,stigative Pathology.
.and by extrapolation, 2750 to 5550 people will develop
PVR.5 Both the small size of this population and the difﬁ-
culty in predicting which patient will succumb to this
afﬂiction make PVR a low priority for the pharmaceutical
industry. Consequently, efforts to develop new therapies for
PVR and evaluate them in clinical trials have languished.
The putative mediators of PVR pathogenesis (growth
factors) also contribute to more common diseases, such as
atherosclerosis and cancer.10e14 Consequently, the beneﬁt
of identifying culprits of PVR and their functional rela-
tionships is likely to extend beyond the scope of PVR.
Pennock et alBreaks in the retina expose cells within and beneath it to
vitreous, which is a rich source of growth factors that are
implicated in PVR pathogenesis.7,15e29 Although vitreous
from both patients and experimental animals with PVR
contain a wide spectrum of growth factors,29 those agents that
act on the platelet-derived growth factor (PDGF) receptor a
(PDGFRa) appear to be especially relevant to PVR patho-
genesis because PDGFRa is associated with clinical PVR
and is required for experimental PVR in the most commonly
used model of this disease.15,30e34 These vitreal agents
include PDGFs and two other classes of growth factors that
inﬂuence activation of PDGFRa, namely, non-PDGFs
[growth factors outside of the PDGF family (eg, insulin
growth factor-1, EGF, human growth factor, and basic
ﬁbroblast growth factor) and vascular endothelial growth
factor A (VEGF-A)].29,35e37
There are at least two ways to activate PDGFRa, and only
the way that results in a decline in the level of p53 effectively
induces PVR.35,36,38,39 Vitreous abounds with non-PDGFs
that activate PDGFRa in the way that reduces p53.29,39
Although PDGFs are also present, their level in vitreous of
patients and rabbits with PVR is insufﬁcient to cause
a substantial decline in the level of p53.38,39 Furthermore,
PDGFs antagonize the ability of non-PDGFs to reduce the
p53 level.37,39 The underlying mechanism appears to involve
PDGF-mediated reduction in the amount of PDGFRa
available to non-PDGFs.39 The results of these biochemical
studies indicate that the key agent in vitreous that drives PVR
is non-PDGFs, whereas PDGFs protect from PVR.
In vivo studies conﬁrmed some, but not all, of these
concepts. Neutralizing vitreal non-PDGFs protected rabbits
from developing PVR, and thereby conﬁrmed the idea that
non-PDGFs were required for experimental PVR.29 In
contrast, inhibiting vitreal PDGFs had no effect.36 In light of
the fact that PDGFs antagonize non-PDGFs, one would have
expected that neutralizing PDGFs should have promoted
PVR. Although these ﬁndings indicated a requirement for
non-PDGFs in experimental PVR, they also indicated that
there were additional concepts that needed to be considered.
For instance, VEGF, which is also present in patients and
experimental animals with PVR,16,20,29,40 competitively
inhibited PDGF from binding and activating PDGFRa.37
Thus, a plausible explanation for why neutralizing PDGFs
had no impact on PVR was because VEGF was already
eliminating their contribution. Furthermore, because PDGFs
antagonize non-PDGFs, then VEGF (by inhibiting PDGF)
should promote the action of non-PDGFs (Figure 1A). This
reasoning led to the prediction that neutralizing VEGF
would inhibit PVR because it would allow PDGF-mediated
inhibition of non-PDGFs, which activate PDGFRa in the
way that leads to PVR.
In the course of investigating this possibility, we discov-
ered that ranibizumab, an antieVEGF-A monoclonal anti-
body fragment, reduced the pathogenic bioactivity of
vitreous from patients and experimental animals with PVR
and protected rabbits from developing this disease. These1660preclinical ﬁndings suggest that one or more of the clinically
approved approaches to neutralize VEGF-A are prophylactic
for PVR. In addition, antieVEGF-based therapies may be
effective for managing more than the angiogenesis and
vascular permeability-driven pathological conditions.
Materials and Methods
Growth Factors, Antibodies, and Major Reagents
Recombinant human PDGF-A, PDGF-AB, and PDGF-B were
purchased fromPeprotech Inc. (RockyHill, NJ). The following
antibodies were raised in the laboratory, as referenced: anti-
PDGFRa,41,42 antiephospho-PDGFRa (Y742),43 and anti-
RasGAP.44 Anti-Akt (9272S) and antiephospho-Akt (pS473
and 9271L) were purchased from Cell Signaling (Danvers,
MA). Antiephospho-PDGFRa (pY720), anti-p53 (sc-126),
PrA-agarose beads (sc-2001), and horseradish perox-
idaseeconjugated goat anti-rabbit and goat anti-mouse IgG
secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Enhanced chemiluminescent
substrate for horseradish peroxidase detection was purchased
from Pierce (Rockford, IL). PDGF TRAP (which binds to and
sequesters PDGF) is a chimera consisting of the extracellular
domain of PDGFRa fused to human IgG Fc5, was provided by
Dr. Debra Gilbertson at ZymoGenetics.42 The antieVEGF-A
Fab fragment, ranibizumab (GENENTECH, South San Fran-
cisco, CA), was a generous gift from Dr. Patricia D’Amore
(Schepens Eye Research Institute, Boston, MA).
Cell Culture and Treatments
Primary rabbit conjunctival ﬁbroblasts (RCFs) were isolated
as described previously.45 These cells were used for analysis
of rabbit vitreous bioactivity and for injection into rabbit eyes
in the experimental PVR model. Primary mouse embryonic
ﬁbroblasts (MEFs) were obtained at third passage from
ATCC (Manassas, VA) and used for the shRNA knockdown
and receptor activation threshold experiments. R627 cells are
immortalized ﬁbroblasts derived from mouse embryos nul-
lizygous for both PDGFR isoforms, in which a full-length
kinase-inactive mutant PDGFRa is re-expressed.15,46 R627
cells were used in experiments to ascertain the role of PDGF-
induced dimerization of PDGFRa in reducing the bioactivity
of vitreous. ARPE-19a cells, derived from the human retinal
pigment epithelial (RPE) cell line, ARPE-19 (ATCC),
overexpress human PDGFRa.41 These cells were used to
investigate the PDGFRa-inhibitory activity of human PVR
vitreous. RPE cells from human PVR membranes (RPEM
cells) were isolated from a surgically removed patient PVR
membrane.47 RPEM cells (at passages 4 to 7) were used
in experiments to assess human vitreous bioactivity. PAE-
KDR cells are pig aortic endothelial (PAE) cells that over-
express human VEGF receptor 2 (VEGFR2), as previously
described48; these cells were used to test whether heat func-
tionally inactivates VEGF-A in PVR vitreous.ajp.amjpathol.org - The American Journal of Pathology
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glucoseecontaining Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Gibco BRL, NY). ARPE-19a, RPEM, and PAE-
KDR cells were maintained in a 1:1 mixture of high-glucose
DMEM and Ham’s F12 medium (Gibco BRL). Cells were
cultured in media supplemented with 10% fetal bovine
serum (FBS), 500 U/mL penicillin, and 500 mg/mL strep-
tomycin, and incubated at 37C in a humidiﬁed 5% CO2
atmosphere.
Cells were grown to near conﬂuence, serum starved
overnight in DMEM with 0.1% FBS, and treated the next
morning. Vitreous (RV-PVR or HV-PVR) that was used to
stimulate cells consisted of an equal-volume pool of several
individual samples. Vitreous or DMEM, supplemented with
the indicated treatments, was added directly to cells after
removal of media and rinsing with PBS. Treatments were
performed under the same conditions as cells that were
incubated (37C in a humidiﬁed 5% CO2 atmosphere).
Preparation of Rabbit Vitreous
Vitreous was extracted from either PVR-positive rabbit eyes
(RV-PVR) or healthy control rabbits eyes (RV) that were
enucleated and frozen at 80C. While still frozen, vitreous
was removed, allowed to thaw to room temperature, and thenFigure 1 Vitreous-driven signaling events and cellular responses
associated with PVR were potentiated by vitreal VEGF-A. A: The functional
relationship between three classes of growth factors present in PVR
vitreous. VEGF-A antagonizes the action of PDGFs, which block non-PDGFs
(growth factors outside of the PDGF family) that activate PDGFRa indirectly
and thereby drive experimental PVR.37,39 B: Neutralizing vitreal VEGF-A
prevented PVR vitreous-driven signaling events. Primary RCFs were serum
starved overnight and either lysed immediately without treatment (d) or
continuously treated for 48 hours with 400 mL RV-PVR supplemented with
10 mg/mL nonimmune IgG, 25 mg/mL neutralizing anti-VEGF antibody,
ranibizumab (a-VEGF), 20 ng/mL PDGF-A, or a combination of 10 mg/mL a-
VEGF and 2 mmol/L PDGF TRAP. After treatment, cells were lysed and the
resulting TCLs were subjected to Western blot analysis using the indicated
antibodies and quantiﬁed (see Materials and Methods). Ratios representing
normalized band intensities are shown under each immunoblot. Blots
shown are representative of three independent experiments. C: Neutralizing
vitreal VEGF-A suppressed PVR vitreous-driven cell contraction. RCFs were
preconditioned for 48 hours with serum-free medium alone (d) or 400 mL
RV-PVR supplemented with 10 mg/mL nonimmune IgG, 25 mg/mL a-VEGF,
2 mmol/L a-VEGF þ PDGF TRAP, or 20 ng/mL PDGF-A; in addition, cells were
preconditioned with a-VEGF, PDGF TRAP, or PDGF-A alone as controls. After
preconditioning, cells were transferred to collagen gels containing the
same treatment and subjected to the collagen gel contraction assay. Gel
area was measured after 24 hours. Data are presented as percentage
contraction of collagen gels measured after 24 hours, and are represented
as mean percentage contraction  SDs obtained for three independent
experiments. D: Neutralizing vitreal VEGF-A prevented PVR vitreous-driven
cell survival. Near-conﬂuent RCFs were placed in starvation medium
(DMEM without serum) for 72 hours as an inducement of apoptosis, during
which time they were conditioned with the same treatments as described in
B. At 72 hours, surviving cells were quantiﬁed as those cells whose nuclei
failed to stain positive for apoptosis (by TUNEL assay, see Materials and
Methods). The graph presents data from three independent experiments
showing the mean percentages of cells ( SD) surviving starvation.
*P < 0.05 using a paired t-test. In each experiment, 12 randomly chosen
ﬁelds were counted. Original magniﬁcation, 100.
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clariﬁed vitreous was used for subsequent analysis. Vitreous
used for treatment is an equal-volumemix from several rabbit
eyes of comparable clinical status (ie, PVR stage).
Western Blot Analysis
Cells were washed twice with ice-cold PBS after treatment,
then lysed in sample buffer (50 mmol/L Tris-HCl, pH 6.8,
10% glycerol, 2% SDS, 1% b-mercaptoethanol, 10 mmol/L
EDTA, and 0.02% bromophenol blue). Total cell lysates
(TCLs) were incubated on ice for 15 minutes, heated to 95C
for 5 minutes, and clariﬁed by centrifugation at 13,000  g,
4C for 15 minutes. Samples were then run on 8% or 10%
acrylamide SDS-PAGE gels, and resolved proteins were
transferred to polyvinylidene diﬂuoride immunoblotting
membranes by semidry transfer. Each immunoblot shown is
representative of three independent experiments. Signal
intensity was determined by densitometry using Quantity
One software version 4.0 (Bio-Rad, Pinole, CA); signal
quantities shown were standardized to background and
normalized for loading.
Cell Contraction Assay
Cells were grown to near conﬂuence and then preconditioned
for 48 hours with the indicated treatment in DMEM before
performing the contraction assay, as previously described.32,49
In brief, 1  106 cells/mL were suspended in a solution con-
taining 1.5 mg/mL neutralized collagen I at pH 7.2 (INAMED,
Fremont, CA) plus the indicated treatment and transferred to
24-well plates pre-incubated with PBS and 5 mg/mL bovine
serum albumin for a minimum of 4 hours. After polymeriza-
tion of the collagen gel (by incubation at 37C for 90
minutes), gels were overlaid with 0.5 mL DMEM supple-
mented with the same indicated treatment. At 24 hours,
collagen gel diameters were measured. At 0 hours, the
diameter of the gel equals the diameter of the well. Triplicate
gels were measured within each experiment. Values shown
are means  SD of at least three independent experiments.
Cell Survival Assay
Cells (RCFs or RPEMs) were seeded onto 60-mm dishes at
1 to 2  105 cells per dish, grown to 80% conﬂuence in
DMEM containing 10% FBS, then rinsed three times with
PBS and cultured in starvation media (DMEM þ 0.1%
FBS) along with the indicated treatments. Media plus
treatment was changed daily. On day 3 (at 72 hours), cells
were rinsed in cold PBS and then apoptotic cells were
quantiﬁed by the TUNEL assay using an apoptosis detection
system, according to manufacturer’s instructions (Promega,
Fitchburg, WI). The percentage of surviving cells was
calculated as follows: (number of nonapoptotic nuclei/total
nuclei analyzed)  100. Because this assay does not account
for dead cells that dislodged from the monolayer and were1662lost during the PBS rinses, the data presented likely under-
represent the actual percentage of cell survival.
Rabbit PVR Model
Dutch-belted adult (aged 3 to 6 months) female rabbits were
purchased from Covance (Denver, PA). PVR was induced
in the right eye of rabbits, as previously described.15,45 In
brief, rabbits were acclimated for 1 week and then injected
with 0.1 mL of perﬂuoropropane gas (Alcon, Fort Worth,
TX) into the vitreous cavity 3 mm posterior to the limbus.
One week later, each experimental eye was co-injected with
2  105 RCFs in 0.1 mL platelet-rich plasma (PRP) and
0.1 mL of balanced salt solution containing either 0.05 mg
antieVEGF-A (RBZ) or the same amount of isotype-
matched control IgG. The PRP is included in the injection
regimen to improve the severity and consistency of the
pathological response to the injected ﬁbroblasts.15
The retinal status was monitored using an indirect
ophthalmoscope (Keeler Instruments, Broomall, PA) with
aþ30-diopter fundus lens (Volk Optical, Mentor, OH) at days
1, 3, 5, 7, 14, 21, and 28 after injection. Intraocular pressures
were monitored daily for 3 days after gas injection and for 1
day after the co-injections (of cells þ PRP and IgG/RBZ)
using a tonometer. PVRwas graded according to the ﬁve-stage
scale of Fastenberg et al,50 described as follows: stage 0, no
disease; 1, epiretinal-membrane formation; 2, vitreoretinal
traction without retinal detachment; 3, localized retinal
detachment of one to two quadrants; 4, extensive retinal
detachment of two to four quadrants, without complete
detachment; and 5, complete retinal detachment. Signs of
toxicity, including intraocular inﬂammation and retinal
hemorrhages, were assessed during each fundus examination
and by histological analysis of retinas after sacriﬁce of
animals. Retinal function was assessed by obtaining single-
ﬂash electroretinograms (ERGs) using a ColorDome stimu-
lator (DIAGNOSYS, Westford, MA) of representative rabbits
at day 26 after injection (both the injected right eye and the
noninjected left eye were measured). Animals were sacriﬁced
at day 28, and eyes were enucleated and frozen at 80C to
preserve their vitreous for later analysis. Surgical procedures
were performed aseptically in conformance with the Associ-
ation for Research in Vision and Ophthalmology Statement for
the Use of Animals in Ophthalmic and Vision Research. The
Schepens Animal Care and Use Committee approved the
protocol used for these animal experiments.
Patient Vitreous
Undiluted patient vitreous was obtained by standard three-
port vitrectomy with removal of vitreous before pars plana
infusion.51 A total of 64 human vitreous samples were
obtained: 32 with PVR and 32 with non-PVR retinal
conditions (principally, macular holes, macular puckers, and
non-rhegmatogenous retinal detachments). Individual sample
volumes ranged from 0.6 to 1.3 mL.ajp.amjpathol.org - The American Journal of Pathology
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(18 PVR and 14 non-PVR) fromUSArmymilitary personnel
donors at the Ophthalmology Service, Department of
Surgery, Walter Reed Army Medical Center (Washington,
DC); 16 (7 PVR and 9 non-PVR) from patient donors at the
Queen Elizabeth II Hospital (Halifax, NS, Canada) and at the
Vancouver Hospital in association with Capital Health
(Halifax) and Vancouver Hospital, University of British
Columbia (Vancouver, BC, Canada); and 16 (8 PVR and 8
non-PVR) from patient donors at the Ocular Angiogenesis
Group, Department of Ophthalmology, Academic Medical
Center, Meibergdreef (Amsterdam, The Netherlands).
Research involving human specimens adhered to the tenets of
the Declaration of Helsinki. Informed written consent was
obtained from all patient donors. Before conducting any
experiments, institutional review board approval was ob-
tained to perform these studies (Schepens Eye Research
Institute Institutional Review Board protocol S-226-0212,
Vitreal Factors in Proliferative Vitreoretinopathy).
Quantifying VEGF-A and PDGFs in Human Vitreous
VEGF-A and PDGFs (comprising the A, AB, and B iso-
forms) were quantiﬁed in individual vitreous samples from
humans with PVR (n Z 32) or with non-PVR retinal
conditions (n Z 32, including macular holes, macular
puckers, or non-rhegmatogenous retinal detachments).
Multiplex bead analysis was performed as previously
described.29 In brief, each vitreous sample (50 mL) was
added in triplicate to a 96-well plate and then incubated
overnight with a mixture of antieVEGF-A, antiePDGF-A,
antiePDGF-AB, and antiePDGF-B monoclonal antibodye-
coated capture beads. Beads were washed and incubated with
biotin-labeled anti-human polyclonal growth factor/cytokine
antibodies for 1 hour, and then streptavidin-phycoerythrin was
added for 30 minutes. Fluorescent emissions distinct to each
growth factor were simultaneously measured using the Bio-
Plex Detection System and the resulting data were analyzed
using BioPlex multiplex software version 2.1 (BioRad).
Growth factor concentrations were determined based on
a series of standards run in parallel.
Statistical Analysis
All data were analyzed using the unpaired t-test or Mann-
Whitney analysis; P < 0.05 was considered statistically
signiﬁcant.
Results
VEGF-A Potentiates the Bioactivity of PVR Vitreous
Previous studies (summarized in Figure 1A) predict that
VEGF potentiates the bioactivity of vitreous (ie, ability to
indirectly activate PDGFRa) by inhibiting PDGF-mediated
suppression of non-PDGFs. This concept predicts thatThe American Journal of Pathology - ajp.amjpathol.orgneutralizing VEGF would promote PDGF-mediated suppres-
sion of indirect activation of PDGFRa. We proceeded to test
this prediction by assessing the impact of neutralizing VEGF
on the bioactivity of vitreous and experimental PVR.
To maximize the translatability of these studies, we
neutralized VEGF using ranibizumab, an Fab fragment of an
antibody that neutralizes VEGF and an agent clinically
approved for ocular use. Ranibizumab is designated a-VEGF
for in vitro experiments and RBZ for in vivo experiments.
Figure 1B shows that a-VEGF diminished the ability of
rabbit PVR vitreous (RV-PVR, which contains non-PDGFs,
PDGFs, and VEGF-A)29 to drive the signature signaling
events of PVR (phosphorylation of PDGFRa, prolonged
activation of Akt, and suppression of p53)39 in primary RCFs.
Varying the concentration of a-VEGF indicated that this
phenomenon was dose dependent (Supplemental Figure S1).
The competitive relationship between VEGF-A and PDGFs,
diagrammed in Figure 1A, predicts that a-VEGF would
derepress PDGFs and thereby promote a decline in the level of
PDGFRa and antagonize nonePDGF-mediated signaling
events.39 Indeed, neutralizing PDGFs by adding PDGF TRAP
eliminated the effect of a-VEGF (Figure 1B), whereas TRAP
alone had no effect (Supplemental Figure S2). Furthermore,
boosting the concentration of PDGFs to a level that outcom-
petes VEGF-A for binding to PDGFRa37 had the same impact
as a-VEGF (Figure 1B). These ﬁndings indicate that neutral-
izing VEGF-A diminished the ability of RV-PVR to stimulate
signaling events associatedwith PVR, and that themechanism
involved derepressing vitreal PDGFs.
We also observed that a-VEGF attenuated the ability of
RV-PVR to induce cellular events associated with PVR,
such as contraction (Figure 1C) and survival (Figure 1D).
As observed for the signaling events, PDGF TRAP coun-
teracted the effect of a-VEGF, whereas increasing the level
of PDGF mimicked it (Figure 1, C and D).
Because PDGF promotes many cellular responses
associated with PVR,15,41 it was somewhat of a surprise
that PDGF diminished the potency of RV-PVR (Figure 1,
BeD). A comparison of PDGF and RV-PVR for their
ability to induce contraction or survival revealed that
PDGF was less potent than RV-PVR in promoting either
response (Figure 1, C and D). Furthermore, because
PDGF blocks non-PDGFs (Figure 1A), the maximum
achievable response when both types of agonists are
present and active (as is the case when a-VEGF dere-
presses PDGFs in RV-PVR) is the lower level that is
attained with PDGF.
Taken together, these ﬁndings indicate that VEGF-A boosts
the bioactivity of RV-PVR. These observations predict that
neutralizing vitreal VEGF-A, and thereby diminishing the
bioactivity of vitreous, will safeguard from PVR.
Neutralizing Vitreal VEGF-A Prevents Experimental PVR
To test if neutralizing VEGF-A protected from experimental
PVR, we used the most common and aggressive model of1663
Pennock et althis disease.30 Fibroblasts co-injected with PRP into vitreous
assemble with extracellular matrix proteins to form a
membrane that attaches to the surface of the retina. Contraction
of this membrane causes retinal detachment. This animal
model mimics those forms of clinical PVR in which the epi-
retinal membrane is responsible for retinal detachment.30
Experimental PVR was induced in 22 rabbits, randomly
divided into two groups that received a single 0.05-mg
injection of RBZ or IgG at PVR induction. The IgG-injected
group developed PVR with the expected kinetics and
severity.36 Within 1 week, 10 (91%) of 11 formed a PVR
membrane (greater than stage 0) and 6 (55%) of 11 had
developed at least partial retinal detachment (stage 3 or
higher) (Supplemental Figure S3). By the end of the exper-
iment (day 28) 9 (82%) of 11 rabbits had retinal detachment
(Figure 2A). Previous studies document that injection of IgG
does not inﬂuence the development of PVR.29,36
A single injection of RBZ dramatically reduced PVR
pathological characteristics. On day 5, 8 (73%) of 11 RBZ-
injected rabbits showed no sign of pathological features
compared with 1 (9%) of the 11 IgG-injected group
(Supplemental Figure S3). The difference between experi-
mental groups was statistically signiﬁcant from day 5 to dayFigure 2 Neutralizing vitreal VEGF-A safely and effectively prevented experim
three separate 0.1-mL injections of PVR-inducing RCFs, PRP, and either 0.05 mg o
The concentration (calculated based on vitreous volume) of RBZ injected was 10-f
only one eye was injected. Rabbits were examined and scored for development of
shown, and the results from all other time points scored are shown in Supplemen
(n Z 11 for each group). Statistically signiﬁcant differences at each time point
rabbits with a-VEGF did not interfere with retinal function. Single-ﬂash ERGs were
both injected and noninjected eyes of the same rabbit after dark adaptation. The E
rabbits per group. The amplitude from the baseline to the a-wave trough (a) reﬂ
photoreceptors), while the amplitude from the a-wave trough to the b-wave p
eyes elicited the same electrophysiological response as their noninjected counte
showed no signiﬁcant difference between RBZ-injected and noninjected eyes (
morphological changes in the retina. Eyes enucleated from a representative RBZ-tr
10% formalin, embedded in methacrylate, divided into sections, and the resultin
retinal detachments; thus, their morphological characteristics were not included in
panel. Retinal layers are indicated: GCL, ganglion cell layer; INL, inner nuclear laye
layer; PRL, photoreceptor layer. These data indicate that a-VEGF/RBZ treatment
166428, when 9 (82%) of 11 versus 0 (0%) of 11 rabbits remained
disease free in the RBZ- and IgG-injected groups, respectively
(Supplemental Figure S3).
Assessment of retinal function indicated that, although the
retina was devoid of electrophysiological activity in eyes that
developed severe PVR (stage 5, total retinal detachment), it
was completely normal in eyes that were protected from PVR
by RBZ (Figure 2B). The morphological characteristic of
retinal sections from RBZ-injected eyes was overtly normal
(Figure 2C). These results indicate that RBZ effectively and
safely prevented PVR in this preclinical model of the disease.
PDGF-Mediated Dimerization Attenuates the
Bioactivity of RV-PVR
Figure 1B shows that derepressing PDGFs in RV-PVR
resulted in a decline in the level of PDGFRa, which is the
expected result given that PDGF promotes internalization
and degradation of PDGFRa. Because this decline in the
level of PDGFRa was associated with a nearly complete loss
of the signature signaling events, it suggested that most of the
pool of PDGFRa was required to trigger these signaling
events. If this were true, then molecularly reducing the levelental PVR (A). One week after an intravitreal gas injection, rabbits received
f a-VEGF ranibizumab (RBZ) or an equimolar amount of isotype control IgG.
old less than the amount typically used in human eyes.52,53 For each rabbit,
PVR over a 4-week period; the results from the last time point (day 28) are
tal Figure S3. Horizontal bars represent the mean PVR stage of each group
were determined by Mann-Whitney analysis (P < 0.001). B: Treatment of
obtained from rabbits on day 26 after injection; readouts were obtained for
RGs shown span 100 milliseconds and are representative of three individual
ects the general physiological health of the outer retina (particularly the
eak (b) reﬂects the health of the inner retinal layers. RBZ-treated rabbit
rpart eyes. Light-adapted, single-ﬂash and light-adapted ﬂicker ERGs also
data not shown). C: Treatment of rabbits with RBZ did not cause major
eated rabbit (PVR stage 0) and a noninjected eye (PVR stage 0) were ﬁxed in
g sections were stained with H&E. Representative IgG-treated rabbits had
this analysis. A representative region of the neural retina is shown in each
r; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform
did not adversely affect the retina.
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ture signaling events. However, this is not what we observed.
RV-PVReinduced activation of Akt and suppression of p53
were comparable in control cells and in cells expressing only
30% of the starting level of PDGFRa (Figure 3A). Although
it is intuitive that reducing the pool of PDGFRa will reduce
the number of receptors available for activation by RV-PVR,
our results indicate that the mechanism by which PDGF
attenuated the bioactivity of RV-PVR involved more than
a reduction in the amount of PDGFRa.
Given that RV-PVR activates PDGFRa monomers,37
whereas PDGF drives monomers into dimers,54,55 we
considered whether PDGF-mediated dimerization of
PDGFRa diminished its ability to be activated by RV. RV is
vitreous from healthy rabbits and was used instead of RV-Figure 3 PDGF-mediated dimerization attenuated indirect activation of PDG
PDGFRa signaling. Lentiviruses were used to stably express shRNAs directed again
shPDGFRa MEFs expressed approximately 70% less receptor than control shGFP MEF
PDGF-A, as indicated for 120 minutes at 37C, then lysed and subjected to Weste
PDGFRa band intensities were normalized to RasGAP levels. These ﬁndings indicate
signaling events in response to RV-PVR. B: Near-conﬂuent MEFs were serum star
increasing concentration of PDGF-A. Cells were treated in parallel for 60 and 120
Western blot analysis using the indicated antibodies. Prolonged Akt phosphorylati
were attenuated at saturating doses of PDGF-A, suggesting that PDGF-induced d
driven indirect signaling of PDGFRa. C: R627 cells were serum starved overnig
minutes at 4C (to ensure complete receptor dimerization on the cell surface), fol
treatment, cells were lysed and subjected to Western blot analysis using antiepho
untreated control. Although indirect activation of PDGFRa still occurred at 4C, re
receptor activation at 37C (Supplemental Figure S4), demonstrating a correlation
further suggesting that PDGF diminishes nonePDGF-mediated activation of PDG
quences of direct and indirect activation of PDGFRa. ROS, reactive oxygen specie
The American Journal of Pathology - ajp.amjpathol.orgPVR because it contains little or no PDGFs or VEGF-A,29
which would complicate the interpretation of the results. A
concentration of 5 ng/mL PDGF was the minimum dose
required to achieve maximal activation of Akt, indicating that
all receptors were dimerized (Figure 3B). This empirical
ﬁnding was consistent with the fact that 2.5 1011 molecules
of PDGFwere required to saturate the approximately 1 1011
PDGFRas that were present. As shown in Figure 3B, RV-
mediated signaling events sharply declined as the concen-
tration of PDGF approached saturation. These results support
the idea that PDGF-mediated dimerization of PDGFRa
reduced its ability to be activated by RV.
Tobegin to understandhowdimerizationcould interferewith
RV-dependent activation of PDGFRa, we considered whether
dimerization inﬂuenced the capacity of PDGFRa to undergoFRa. A: Reduction of PDGFRa levels by shRNA did not attenuate indirect
st green ﬂuorescent protein (GFP; shGFP) or PDGFRa (shPDGFRa) in MEFs;
s. Cells were then starved and treated with 400 mL RV-PVR and/or 20 ng/mL
rn blot analysis using the indicated antibodies. Both immature and mature
that no more than 30% of the total pool of PDGFRa was required to trigger
ved overnight and treated with 400 mL DMEM or RV supplemented with an
minutes, after which time they were harvested and TCLs were subjected to
on and reduction in p53 levels (indicators of indirectly activated PDGFRa)39
imerization is a key component of PDGF-mediated attenuation of vitreous-
ht and either left alone or pre-incubated with 10 ng/mL PDGF-A for 30
lowed by treatment with or without 400 mL RV for 10 minutes at 4C. After
spho-PDGFRa, followed by anti-pan PDGFRa, and normalized relative to the
ceptor activation was approximately 2.5-fold lower compared with indirect
between dimerization and reduced capacity to undergo indirect activation,
FRa by dimerizing PDGFRas. D: Schematic showing the details and conse-
s; SFK, Src-family kinases.
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Figure 4 PDGF-dependent activation of PDGFRa was inhibited by VEGF-A, a heat-labile, PDGFRa-associated agent in human PVR vitreous. A: Patient PVR
vitreous contains inhibitory activity against PDGF-mediated PDGFRa activation. ARPE-19a cells were grown to near conﬂuence, serum starved overnight, and
then treated with serum-free medium alone (d), 200 mL human patient PVR vitreous (HV-PVR), 10 ng/mL PDGF-A, or both HV-PVR and PDGF-A for 5 minutes at
37C. Cells were lysed and subjected to antiephospho-PDGFRa (p-PDGFRa) and then anti-PDGFRa Western blot analysis. The p-PDGFRa immunoblot signal was
normalized to total PDGFRa (PAN) and is presented as fold induction over the non-stimulated control. Blots shown are representative of three independent
experiments. HV-PVR reduced PDGF-mediated activation of PDGFRa by approximately 50%, suggesting that patient PVR vitreous contains an inhibitor of PDGF-
mediated PDGFRa activation. B: Inhibitory activity in human patient PVR vitreous (HV-PVR) is labile to heat. In a manner similar to A, cells were starved and
treated with serum-free medium without treatment (d), 200 mL HV-PVR, 10 ng/mL PDGF-A, or both HV-PVR and PDGF-A; some HV-PVR treatments were ﬁrst
heat treated to 90C for 5 minutes and then rapidly cooled on ice. Cells were treated for 5 minutes at 37C and lysed, and the resulting TCLs were subjected to
the same Western blot analysis as in A. Although PDGF-A largely survived the heat treatment, nearly all PDGF-inhibitory activity was eliminated from HV-PVR.
Moreover, there were enough endogenous PDGFs in heat-treated HV-PVR to elicit a 3.5-fold activation of PDGFRa (over the non-stimulated control). Thus, heat
treatment unmasked the ability of HV-PVR to activate PDGFRa, suggesting the presence of a heat-labile inhibitor that blocks vitreal PDGFs from functioning. C:
HV-PVRemediated inhibition of PDGF-dependent PDGFRa could be overcome by increasing the concentration of PDGF. Cells were cultured and starved as
described in A. The indicated amount of PDGF-A was added to either 200 mL DMEM or HV-PVR and then used to treat cells for 5 minutes at 37C. Cells were lysed
and subjected to Western blot analysis, and the results were quantiﬁed as in Figure 1. Results from three independent experiments revealed that HV-PVR
signiﬁcantly inhibited PDGFRa phosphorylation at low doses of PDGF-A: 1, 2.5, 5, and 10 ng/mL. *P < 0.05 using a paired t-test. D: Cells preconditioned
with patient PVR vitreous became resistant to subsequent treatment with PDGF-A. Cells were cultured and starved, as described in A, then pre-incubated for 15
minutes at 37C with either DMEM or 200 mL HV-PVR. After incubation, the media/vitreous was removed and cells were extensively washed with PBS, after
which they were treated with serum-free medium alone (d) or 10 ng/mL PDGF-A for 10 minutes at 37C. Cells were subsequently lysed, and the resulting TCLs
were subjected to Western blot analysis with the indicated antibodies. These data suggest that the inhibitor(s) present in HV-PVR acted at the level of cells. E:
Preclearing HV-PVR vitreous with PDGF TRAP signiﬁcantly reduced its ability to inhibit PDGFRa activation by exogenously added PDGF. HV-PVR (200 mL) was
not manipulated or precleared with 2 mmol/L PDGF TRAP or an equimolar amount of a control IgG-Fc fragment (IgG-Fc). These clariﬁed samples were then
tested for their ability to block PDGFRa activation by exogenously added PDGF-A. To this end, cells were treated with clariﬁed vitreous and 10 ng/mL PDGF-A
for 10 minutes at 37C. Serum-free media without treatment (d) and 10 ng/mL PDGF-A alone were used as negative and positive controls, respectively. Cells
were lysed, and the resulting TCLs were subjected to the same Western blot analysis as used in A. The ability of PDGF TRAP to reduce PDGF-inhibitory activity
from HV-PVR suggests that this inhibitor can associate with the extracellular domain of PDGFRa. F: Neutralizing VEGF-A in human PVR vitreous with rani-
bizumab enabled vitreal PDGFs to activate PDGFRa. Cells were serum starved overnight and either lysed immediately (d) or treated for 10 minutes at 37C with
10 ng/mL PDGF-A, 10 mg/mL a-VEGF, or 200 mL HV-PVR supplemented with 10 mg/mL nonimmune IgG, 10 mg/mL a-VEGF, or a combination of 10 mg/mL a-
VEGF and 2 mmol/L PDGF TRAP. After treatment, cells were lysed and the resulting TCLs were subjected to Western blot analysis using the indicated antibodies
and quantiﬁed. Ratios representing normalized band intensities are shown under each immunoblot. Blots shown are representative of three independent
experiments. These results show that neutralizing VEGF-A signiﬁcantly enhanced the ability of vitreal PDGFs to activate PDGFRa.
Pennock et alRV-mediated phosphorylation, an event that is tightly associ-
ated with RV-dependent activation of PDGFRa.35,39 Indeed,
PDGFdiminishedRV-dependent phosphorylation of PDGFRa
(Figure 3C and Supplemental Figure S4), which supported
the idea that monomeric receptors were more efﬁciently acti-
vated by the indirect route than dimerized receptors. These1666experiments were done with kinase-inactivated PDGFRa at
4C to avoid PDGF-dependent autophosphorylation and
internalization. We conclude that, in addition to reducing the
overall level of PDGFRa on the cell surface, PDGF also
attenuatedRV-mediated activationofPDGFRa and subsequent
signaling events by dimerizing PDGFRa (Figure 3D).ajp.amjpathol.org - The American Journal of Pathology
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Also Present in Human PVR Vitreous
To what extent does the pathogenesis of experimental PVR
relate to clinical PVR? Vitreous is readily available from
both experimental animals and patients, and we focused on
this opportunity to begin to address this question. More
speciﬁcally, we considered whether the growth factors and
their relationships, which deﬁne the bioactivity of RV-PVR
(Figure 1A), were comparable in RV-PVR and human PVR
vitreous (HV-PVR).
As rabbits develop PVR, the composition of vitreous
changes (ie, there is an increase in VEGF-A, PDGFs, and non-
PDGFs).29 A similar difference is observed when comparing
vitreous frompatientswith PVRversus vitreousof patientswith
retinal issues unrelated to PVR.16,20,29,40 Furthermore, PDGFs
in both experimental and clinical PVRvitreousunderperform.36
To test if this distinguishing feature ofHV-PVRbioactivitywas
due toVEGF-A, as is thecase forRV-PVR,37we subjectedHV-
PVR to the following series of experiments.
In addition to diminishing PDGF-dependent activation
of PDGFRa by PDGFs that were present in vitreous,29,41 HV-
PVR had a similar inhibitory impact on exogenously added,
recombinant PDGF (Figure 4A). Because certain PDGFs are
more thermally stable thanVEGF-A,37,56 a simpleway tobegin
to assess if the vitreal inhibitor was VEGF-A was to test if
heating HV-PVR mitigated its ability to interfere with PDGF-
dependent activation of PDGFRa. As shown in Figure 4B,
heating HV-PVR increased the potency of the PDGFs in
vitreous and diminished the ability of HV-PVR to interfere
with activation of PDGFRa by recombinant PDGF. Heating
HV-PVRalso reduced its ability to promote phosphorylation ofThe American Journal of Pathology - ajp.amjpathol.orgVEGFR2 (Supplemental Figure S5), which is consistent with
the heat sensitivity of puriﬁed VEGF-A.37 Furthermore,
increasing the concentration of PDGF in HV-PVR overcame
the inhibitory action of vitreous (Figure 4C). These results
supported the idea that VEGF-A was a heat-labile agent that
antagonized PDGF-dependent activation of PDGFRa.
In the context of RV-PVR, VEGF-A acted at the level of
PDGFRa (ie, by competitively inhibiting vitreal PDGFs
from binding and activating PDGFRa).37 We performed the
following two experiments to test if the same was true for
HV-PVR. First, pretreating cells with HV-PVR rendered
them resistant to subsequent PDGF-dependent activation of
PDGFRa (Figure 4D). Second, passing HV-PVR over
a matrix coupled to a fusion protein that included the
extracellular domain of PDGFRa diminished the ability of
HV-PVR to suppress activation of PDGFRa by recombi-
nant PDGF (Figure 4E). We concluded that HV-PVR acted
at the level of PDGFRa (instead of at the level of PDGFs).
Finally, if the relationship between VEGF-A, PDGFs, and
non-PDGFs in HV-PVR was the same as in RV-PVR
(Figure 1A), then addition of a-VEGF to HV-PVR should
derepress vitreal PDGFs to activate PDGFRa. This is whatwe
observed (Figure 4F). Taken together, these studies demon-
strate that the VEGF-A/PDGF/non-PDGF relationship that
deﬁnes the bioactivity of RV-PVR (Figure 1A) is likely
a critical element of HV-PVR bioactivity as well.
VEGF-A Potentiates the Bioactivity of Human PVR
Vitreous
The results fromFigure 4 predict that neutralizingVEGF-Awill
diminish the bioactivity of HV-PVR in a PDGF-dependentFigure 5 Neutralizing VEGF-A in human PVR
vitreous prevented PVR-associated signaling events
and cellular outcomes in RPE cells isolated from
a human PVR membrane. Experimental data shown
in AeC were performed similarly to those of
Figure 1, BeD, with the exception that, in these
experiments, HV-PVR was used (instead of RV-PVR)
to stimulate PVR membrane-derived RPE cells
(instead of RCFs). D: Comparison of VEGF-A and
PDGF levels in the vitreous of patients with or
without PVR. Vitreous from patients with PVR or
non-PVR retinal diseases (macular holes or macular
puckers) was subjected to multiplex analysis to
determine the concentration of VEGF-A and PDGFs
(total of A, AB, and B isoforms). Although 94% of
PVR samples had a detectable level of VEGF-A, the
same was true for only 34% of non-PVR samples.
Molar amounts of VEGF-A and PDGFs in each sample
were frequently detected at similar levels (symbols
labeled with the same letter are the same sample).
Most had low levels of both, whereas when PDGFs
were present, there was also a matched (samples A
to C) or slightly elevated (samples D to H) amount
of VEGF-A. These observations indicate that the
ratio of vitreal VEGF-A/PDGF correlates with clinical
PVR and is a potential biomarker for PVR suscepti-
bility. *P < 0.05 using a paired t-test.
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Pennock et almanner. Subsequent experiments were done with RPEM cells
to further strengthen the relevance to clinical PVR.47 Similar to
the results with RV-PVR (Figure 1), a-VEGF reduced HV-
PVRemediated activation of PDGFRa and the subsequent set
of signature signaling events (Figure 5A). Neutralizing PDGFs
(by adding PDGFTRAP) eliminated the effect ofa-VEGF, and
increasing the concentration of PDGF had the same effect as
a-VEGF (Figure 5A). These ﬁndings indicate that a-VEGF
diminished the ability of HV-PVR to stimulate signaling events
associated with PVR by derepressing vitreal PDGFs.
We also observed that a-VEGF attenuated the ability of
HV-PVR to induce cellular events associated with PVR,
such as contraction (Figure 5B) and survival (Figure 5C).
As observed for the signaling events (Figure 5A), PDGF
TRAP mitigated the a-VEGF effect, whereas increasing the
level of PDGF mimicked it (Figure 1, C and D). We
conclude that, such as RV-PVR, VEGF-A potentiates the
PVR potential of HV-PVR because of the VEGF-A/PDGF/
non-PDGF relationship (Figure 1A). Clinical studies are the
next logical step to test if neutralizing VEGF-A protects
patients from PVR, as it does in the preclinical studies.
The VEGF-A/PDGF Ratio Is a Potential Biomarker for
Susceptibility to PVR
If the VEGF-A/PDGF ratio is related to the pathogenesis of
clinical PVR, then only certain ratios should be present in the
vitreous of patientswhodevelopPVR.Assuming that the level
of non-PDGFs is sufﬁcient to activate PDGFRa (a reasonable
assumption given that vitreous of patients with PVR is
a cornucopia of non-PDGFs),16,17,19,21e24,26,27,29,57 then
vitreous from patients with PVR should either have matched
levels of both VEGF-A and PDGFs or VEGF-A should be
greater that PDGFs, because either scenariowill be permissive
for non-PDGFs to activate PDGFRa (Figure 1A). Analysis of
the level of VEGF-A and PDGFs in vitreous from 32 patients
with PVR showed that this was indeed the case (Figure 5D).
Most had low levels of both, whereas when PDGFs were
present, there was also a matched (samples A to C) or slightly
elevated (samples D to H) amount of VEGF-A. These obser-
vations indicate that the ratio of vitreal VEGF-A/PDGFs
correlates with clinical PVR and is a potential biomarker for
PVR susceptibility. Perhaps the next step is to prospectively
test if theVEGF-A/PDGFs ratio of the vitreous collected at the
initial surgery for RD repair can predict subsequent PVR.
Discussion
We found that VEGF-A promoted the bioactivity of vitreous
from patients and rabbits with PVR, and that the mechanism
involved repressing PDGFs. Furthermore, neutralizing
vitreal VEGF-A by intravitreally administering RBZ pro-
tected rabbits from PVR. Finally, the vitreal VEGF-A/
PDGFs ratio is a potential indicator of PVR susceptibility.
TRAP (a fusion protein consisting of an antibody Fc domain
and the extracellular domain of PDGFRa) binds to both1668PDGFs and VEGF-A.37 In many of the experiments described
herein, TRAP was used to test if the increased bioactivity of
vitreous, which was observed on neutralizing VEGF, was
dependent on PDGF. In these types of experiments, the ability
of TRAP to bind VEGF was irrelevant (because VEGF was
already neutralized by a-VEGF) and, hence, did not preclude
the interpretation of such experiments.
What is the likelihood that preclinical data presented
herein are accurate guides for developing an effective PVR
prophylaxis? The similarities between experimental and clin-
ical PVR vitreous strongly support such a possibility.
Furthermore, there appears to be a link between PVR and p53
in both experimental and clinical PVR. In rabbits, PDGFRa-
mediated reduction of the level of p53 is required for PVR.38
The level of p53 in the retina of patients with PVR is lower
than in individuals without PVR.58 Similarly, RRD patients
harboring a single-nucleotide polymorphism in p53 are pro-
tected fromPVRincertain populations.59Taken together, these
ﬁndings constitute a reasonable foundation for a clinical trial
testing clinically approved antieVEGF-A reagents, such as
ranibizumab, to protect patients from developing PVR. The
design of such a study should accommodate the fact that there
are probably multiple forms of PVR, the putative existence of
ill-deﬁned genetic and/or environmental contributors to PVR,
and lessons available from previous clinical trials.52,60
The relationship between vitreal growth factors (Figure 1A)
reveals which of them are likely to be the best therapeutic
targets.NeutralizingPDGFs should be ineffective, because they
are already inhibited by VEGF-A. This prediction is consistent
with ourﬁndings that several approaches to block PDGFs failed
to affect PVR.36 Moreover, a mutant PDGFRa that lacks the
extracellular domain and cannot be activated by PDGFs is fully
capable of inducing PVR.36 In contrast, neutralizing non-
PDGFs or VEGF-A is likely to be effective, and this is what
we observed (Figure 2A).29 In light of the fact that many non-
PDGFs are capable of indirectly activating PDGFRa, a combi-
nation of neutralizing agents is necessary to prevent PVR.29 In
contrast, monotherapy directed at VEGF-A is simpler andmore
effectively protects from even the earliest stages of PVR
(formation of a membrane) (Figure 2A and Supplemental
Figure S3). Thus, VEGF-A appears to be the best vitreal target.
Not including a nonimmune Fab control group in the
experiment shown in Figure 2 leaves open the question of
whether any Fab fragment protects rabbits from developing
PVR. The likelihood of this possibility seems low because
the known function of Fab fragments is to bind antigens.
Such as Fab fragments, intact antibodies bind antigens. The
control group that was included in Figure 2 was injected
with a nonimmune IgG, which failed to protect rabbits from
PVR, despite the fact that each IgG molecule contained two
Fabs. This observation suggests that individual Fab frag-
ments would likewise fail to protect from PVR. Moreover,
antibodies directed against growth factors other than VEGF-
A were also unable to protect from PVR.36 These data,
together with the knowledge of how antibodies function,
strongly support the interpretation of Figure 2A that onlyajp.amjpathol.org - The American Journal of Pathology
Ranibizumab Prevents Experimental PVRFab fragments capable of neutralizing VEGF-A prevented
experimental PVR.
A single injection of RBZ, which effectively prevented
rabbits from developing PVR, may be insufﬁcient to protect
patients. Unlike patients, rabbits do not undergo a mechanical
vitrectomy and, therefore, RBZ clearance from the vitreous
cavity will be slower because vitreous is present.1,3,53 In addi-
tion, susceptibility to PVR lasts several weeks after RRD repair.
Multiple injections of RBZ are likely to be necessary to achieve
a persistent level of RBZ sufﬁcient to protect patients from
developing PVR. Repeated intravitreal injections of ranibizu-
mab are already being used in the treatment of ophthalmic
diseases. They are considered safe and can be performed
quickly and with minimal discomfort in the ofﬁce.53,61
The published contributions of PDGFs in PVR include both
promoting and suppressing PVR.30,36,37,39,62 This paradox can
be resolved by considering that the dose of PDGF inﬂuences its
effect. At a high level (500 ng/mL), PDGF begins to induce the
types of signaling events that are triggered by nonePDGF-
mediated activation of PDGFRa (namely, prolonged activation
of Akt and suppression of p53).39 Publications indicating that
PDGFspromotePVR typically used ahighdose.30,62 In contrast,
at the level observed in PVR vitreous (<100 ng/mL), PDGFs
antagonize nonePDGF-mediated signaling events because they
assemble PDGFRa into dimers, which are less capable of being
activated by non-PDGFs. We conclude that PDGFs can either
promote PVR (provided that the dose is sufﬁciently high) or
attenuate it, which occurs when the dose is in the range observed
in both experimental and clinical PVR vitreous.
The results presented herein indicate that inhibition of
VEGF-A is potentially useful in treatment of diseases without
angiogenesis or increased vascular permeability. In addition,
because some of the mediators of PVR pathogenesis also
contribute to more common diseases, such as atherosclerosis
and cancer,10e14 identiﬁcation and characterization of these
factors in PVR and their functional relationships are likely to
extend beyond the scope of this disease.
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